Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peglosenatide versus metformin for weight change in overweight or obese adults with type 2 diabetes
ChiCTR2200057800Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Change in body weight from baseline. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2200057800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057800.